Skip Page Header

Home > Report on the risk assessment of methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA) in the framework of the Council Decision on new psychoactive substances.

European Monitoring Centre for Drugs and Drug Addiction. [EMCDDA] (2017) Report on the risk assessment of methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA) in the framework of the Council Decision on new psychoactive substances. Luxembourg: Publications Office of the European Union. 51 p. Risk Assessments 19

[img]
Preview
PDF (Report on the risk assessment of methyl 2)
680kB

This publication presents the data and findings of the risk assessment on methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA), carried out by the extended Scientific Committee of the EMCDDA on 22 July 2016. MDMB-CHMICA is the first synthetic cannabinoid receptor agonist to be risk-assessed by the EMCDDA. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 27 February 2017, the Council decided that MDMB-CHMICA should be subject to control measures across the Member States.

Table of contents:
• Foreword
• EMCDDA actions on monitoring and responding to new drugs
• EMCDDA–Europol Joint Report on MDMB-CHMICA — a summary
• Risk Assessment Report on a new psychoactive substance: MDMB-CHMICA
• Annex 1: Technical report on MDMB-CHMICA
• Council Decision on subjecting MDMB-CHMICA to control measures
• Participants of the risk assessment meeting


Item Type
Evidence resource
Publication Type
Report
Drug Type
New psychoactive substance
Intervention Type
AOD disorder harm reduction
Source
Date
March 2017
Pages
51 p.
Publisher
Publications Office of the European Union
Corporate Creators
European Monitoring Centre for Drugs and Drug Addiction
Place of Publication
Luxembourg
EndNote
Related URLs

Repository Staff Only: item control page